Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

h submissions will be accepted or approved, Optimer's ability to enter into partnerships on favorable terms or at all, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    Contacts

    Optimer Pharmaceuticals, Inc.
    John Prunty, CFO & VP, Finance
    Christina Donaghy, Corporate Communications Manager
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005
                          Optimer Pharmaceuticals, Inc.
                      Consolidated Statements of Operations
                                   (unaudited)

                            Three Months Ended          Nine Months Ended
                               September 30,               September 30,
                               -------------               -------------
                             2009         2008          2009          2008
                             ----         ----          ----          ----
    Revenues:
      Research grants     $176,202     $239,212      $583,992      $844,675
      Collaborative
       research
       agreements                -            -       100,000        50,000
                               ---          ---       -------        ------
        Total revenues     176,202      239,212       683,992       894,675
    Operating expenses:
      Research and
       development       7,192,383    7,877,906    26,519,447    21,003,764
      Marketing            393,864      415,916     1,179,212     1,695,400
      General and
       administrative    2,030,137    1,544,925     5,949,946     4,803,422
                         ---------    ---------     ---------     ---------
        Total operating
         expenses        9,616,384    9,838,747    33,648,605    27,502,586
                         ---------    ---------    ----------    ----------
    Loss from
     operations         (9,440,182)  (9,599,535)  (32,964,613)  (26,607,911)
  
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email: